On August 9, 2022, Medicenna Therapeutics Corp. (NASDAQ:MDNA) filed a voluntary supplement with the U.S. SEC that contained an update on the ongoing Phase 1/2 ABILITY Study (A Beta-only IL-2 ...
Range requests enable you to retrieve partial content in lieu of the entire content for improved performance when working with WebAPI over HTTP. HTTP 1.1 provides support for range headers – it allows ...
-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback